AstraZeneca Plc reported revenue of $6.3 billion for the second quarter, which was an increase of 2% when expressed in constant exchange rates, enabling the company to declare six successive quarters of top-line growth and to revise upward its guidance for 2015.
GlaxoSmithKline Plc expects to see earnings grow again in 2016 following a reshaping of its business to focus on pharmaceuticals, vaccines and consumer healthcare and reducing its dependence on the off-patent respiratory medicine Advair.
MorphoSys AG has confirmed its financial guidance for 2015 with expectations of revenue of between €101 and €106 million, and earnings before interest and tax of €9 to €16 million. This follows an eventful period during which it saw a multi-year partnership with Celgene Corp end.
A three-year collaboration between Ablynx NV and Merck & Co. Inc in immuno-oncology has been extended by one year in order to enable the parties to investigate up to 12 new molecules targeting individual protein targets and combinations of targets that could potentially treat cancer, Ablynx announced the new agreement on 22 July.
A new vaccine designed to protect young children in sub-Saharan Africa from infection from thePlasmodium falciparum parasite has been given a positive opinion by the European Medicines Agency even as its effectiveness was described as modest.
Oxford Nanopore Technologies Ltd has raised £70 million through a private placement of shares with new and existing investors in the UK, US and continental Europe to support development of the company’s electronic molecular analysis systems.
Roche has confirmed its forecast for a modest growth in sales this year with core earnings per share advancing ahead of sales. In the first half, the increase in sales was restrained by a strengthening of the Swiss franc against the euro.
Shire Plc posted a 3.7% gain in revenue to $1.56 billion in the second 2015 quarter but hefty impairment charges brought a 60.8% decline in operating income to $132.6 million.
Despite reporting weaker revenue and a decline in operating profit for the second quarter, Novartis has maintained its forecast for growth for the year as a whole, on the strength of an improved performance of its Sandoz generics subsidiary.
Five months after appointing a new chief executive, Sanofi SA has announced a major reorganisation of its global business that highlights the company’s portfolio of medicines for rare diseases, diabetes and cardiovascular disease.